Dronabinol for Sickle Cell Pain and Inflammation
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 60 (estimated)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Other
This trial is looking for adults with sickle cell disease who experience pain and inflammation. Participants will take dronabinol to see if it helps reduce their symptoms over a period of 8 weeks.
You may be able to join if
- I am over 18 years old
- I have sickle cell disease
- I have a pain score of 60 or lower
- I have been on my sickle cell treatment for at least 3 months
- I have been taking my pain medication for at least 3 months
- I can consent to participate in research
- I am willing to use birth control if I can become pregnant
You may not be able to join if
- I have had issues with dronabinol or marijuana in the past
- I have a history of psychosis or suicidal thoughts
- I cannot take dronabinol because of other medications or health problems
- I am pregnant or nursing
- I use cannabis daily
- I have an active substance use disorder
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityA randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).
Loading trial locations…